e IL-10R2 chain is broadly expressed, whereas IL-22R is preferentially expressed on epithelial cells. 2 IL-22 promotes the proliferation of various epithelial cells, including skin, colon, and lung epithelial cells. Furthermore, IL-22 induces serine proteases, matrix metalloproteinases, and some serpin family protease inhibitors from keratinocytes, supporting its role in wound healing, tissue remodeling, and re-epithelialization. 8 -10 Taken together, IL-22 may help to restore the barrier function of damaged epithelia during in ammation. In addition, IL-22 enhances the innate immune responses of the tissues by stimulating the production of antimicrobial peptides from epithelial cells, which we will discuss further. It also activates epithelial cells to secrete proinammatory chemokines and cytokines ( Figure 1 ). 8 -10 ese data point toward a proin ammatory role for IL-22 in tissue immunity.
IL-22 IN MUCOSAL IMMUNE DEFENSES
e mucosal surfaces, such as the lung and gastrointestinal tract, are the key battle grounds for hosts to ght against the invasion of various microbes. Recent studies on the IL-22 pathway in infectious disease models have elucidated its essential protective role in mucosal immunity against bacterial pathogens. 6,7 During K. pneumonia infection of the lung, IL-17A and IL-22, presumably produced by 17 cells, synergistically protect the integrity of the bronchial epithelial layer by inducing proin ammatory chemokines, cytokines, and antimicrobial peptides. e lack of either IL-17 or IL-22 signi cantly compromises the host defense against K. pneumonia invasion. 7 C. rodentium is an attaching and e acing bacterium that speci cally attacks murine colon epithelial cells. e infection of C. rodentium in wild-type mice can result in infectious ( Figure 1 ). In autoimmune encephalomyelitis, Klebsiella pneumonia infection in the lung, and Citrobacter rodentium infection in the colon, the upregulation of IL-22 is abolished in IL-23-de cient mice. 5 -7 IL-22 receptor is composed of the IL-22R chain and the IL-10R2 chain.
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Recent studies in infectious disease and autoimmune disease models have revealed that interleukin ( IL ) -22 might have both proinflammatory and anti-inflammatory functions. There is, however, lack of evidence for IL-22 directly repressing immune responses of leukocytes. We propose that IL-22 promotes innate immunity of tissues, as well as repairing and healing mechanisms during inflammation. Consequently, the restoration of tissue homeostasis helps to attenuate the inflammatory responses involving various immune cells.
COMMENTARIES
nature publishing group colitis in the rst 2 -3 weeks, but it is usually self-resolved a er the development of the adaptive immune responses in the host, particularly the C. rodentium -speci c antibody response. Interestingly, in the absence of IL-22, but not IL-17 signaling, C. rodentium infection causes much more severe damage to the colon epithelial layer, systemic dissemination, and mortality. 6 IL-22 directly targets colon epithelial cells and induces the expression of antimicrobial peptides, such as the Reg family proteins. In contrast to the production of IL-22 by T cells during K. pneumonia infection, the production of IL-22 during C. rodentium infection is independent of T and B cells. Innate immune cells, such as dendritic cells, are the major cellular sources of IL-22 during the early phase of infection. 6 ese data support crucial protective functions of IL-22 in mucosal immunity during the infection by extracellular bacteria.
IL-22 IN IBD: PATHOGENESIS VS.
PROTECTION
What are the functions of IL-22 in inflammatory bowel diseases (IBD)? Recently, genome-wide association studies linked IL-23R to human IBD. 11 e IL-23R chain is one component of 16 Given the critical functions of IL-23 in driving IL-22 production from various immune cells, one might conclude that IL-22 also promotes pathogenesis of human IBD. e story, however, is more complicated. Many preclinical studies thus far have suggested that IL-22 may play a protective role in the gut. In ulcerative colitis and CD patients, IL-22 has been found circulating in the blood and in CD4 + T cells of the colon. 17 -19 Expression of IL-22 is augmented upon progression of disease in dextran sulfate sodium-induced colitis, 18 C. rodentium infection-induced colitis, 6 and T-cell receptor-knockout model of colitis. 20 In addition to its protective role in infectious colitis, as we discussed before, IL-22 also alleviates disease severity in both T-cell receptor-knockout and dextran sulfate sodium models of colitis. 20 In these models, IL-22 helps to restore goblet cells and enhance mucus production. In summary, these data suggest that the augmented IL-22 in IBD may facilitate restoration of the normal homeostasis of intestinal epithelial cells. However, we cannot exclude the potential pathogenic role of IL-22 in other models of IBD. nature publishing group
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As discussed before, IL-22 induces the production of various antimicrobial peptides from epithelial cells. 2 Genes induced by IL-22 in colon cells include the S100 and Reg families of proteins 6 ( Figure 1 ). The functions of these antimicrobial proteins in IBD are still largely unclear. S100A8 and S100A9 are calcium-binding proteins produced by neutrophils, monocytes, and epithelial cells under in ammatory conditions. 21 S100A8 and S100A9 are components of the heterodimeric protein calprotectin. An increased expression of S100A8 and S100A9 is associated with human ulcerative colitis and CD, as well as mouse models of colitis. One postulation is that during in ammation, these proteins can bind endothelial cells and aid in leukocyte extravasation. Recent data, however, suggest that calprotectin can inhibit the growth of Staphylococcus aureus in abscesses by chelation of nutrient Mn 2 + and Zn 2 + . RegIII and RegIII are both induced during bacterial colonization in the gut and in an otherwise in amed colon. 22 Expression of the RegIII proteins is also increased in human ulcerative colitis and CD, as well as in mouse models of IBD. 23 In vitro , RegIII kills Gram-positive bacteria and RegIII can aggregate Escherichia coli . 22 In the small intestine, the upregulation of RegIII is dependent on the colonization by commensal bacteria. In the colon, however, IL-22 is critical for the induction of Reg family protein expression during C. rodentium infection. Recombinant RegIII can partially rescue mortality associated with the loss of IL-22 following C. rodentiuminduced colitis. 6 Finally, lipocalin 2 is an antimicrobial protein expressed in colon epithelial cells and leukocytes in the CD colon. 24 The antibacterial function of lipocalin 2 is thought to be mediated by sequestering iron away from the pathogen. Given that IL-22 induced lipocalin 2 in human skin keratinocytes and mouse tracheal epithelial cells, 7, 10 it is likely that IL-22 can also directly induce lipocalin 2 in the gastrointestinal tract, although this has not been experimentally demonstrated. Despite the convincing data regarding these antimicrobial proteins in controlling the invasion of pathogens in the gastrointestinal tract, there is a lack of conclusive data on their roles in human IBD. Future studies focusing on the role of these proteins in IBD will also facilitate our understanding of the biology of IL-22 in the pathogenesis of IBD.
In summary, it is important to determine the functions of IL-22 and its downstream mediators in human IBD, particularly if we want to design better strategies to treat human IBD by targeting the IL-23 pathways.
PROINFLAMMATORY AND ANTI-INFLAM-MATORY ROLES OF IL-22
IL-22 not only shares structural homology with IL-10, but also uses the IL-10R2 chain as one component in its receptor complex. In addition, both IL-10 and IL-22 activate Stat3, as well as enhance the expression of SOCS3. 25 ese data lead to the speculation that IL-22 may play a similar anti-in ammatory role as does IL-10 during immune responses. Indeed, as we previously discussed, in autoimmune colitis and C. rodentium -induced infectious colitis, lack of IL-22 resulted in exacerbated tissue in ammation. 6, 20 Furthermore, IL-22 also protects against liver damage caused by the in vivo administration of concanavalin A. 26, 27 IL-10 targets various immune cells and inhibits the production of many proin ammatory cytokines from these cells. Similar functions, however, have not been observed for IL-22, mainly because IL-22R is not expressed by immune cells. 2, 25 An alternative hypothesis is that IL-22 exerts its anti-in ammatory functions on epithelial cells. is premise, however, contradicts the proin ammatory functions of IL-22 observed in vitro , in infectious diseases and inflammatory skin diseases. 2 It is possible that IL-22 plays distinct roles in di erent epithelial cells, for example, promoting immune responses in keratinocytes and repressing in ammation in hepatocytes. Further research is needed to provide solid data to support this hypothesis. On the other hand, the protective benefit observed in IBD and hepatitis may simply re ect the consequences of tissue protection and repair of IL-22. By restoring the tissue epithelial barrier, IL-22 may help to sequester leukocytes from the proinflammatory stimuli produced by pathogens or dying tissues and consequently block the further ampli cation of the immune responses. This premise may provide a coherent explanation for the convoluted results seen in the studies of IL-22.
In conclusion, in the classic Th1 and 2 dichotomy model, 1 cells and the downstream e ector cytokines promote cellular immunity by activating CD8 cells, natural killer cells, and macrophages, all of which control infection by intracellular microbes. 28 2 cells, on the other hand, are essential for humoral immunity and are specialized to protect hosts from the invasion of parasites, such as helminths.
e recently identi ed 17 cells preferentially produce IL-17A, IL-17F, IL-22, and IL-21. 13 
